Socioeconomic factors play a more important role than clinical needs in the use of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes.
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Off-label semaglutide (for T2D) use in the obesity-only group underscores access barriers.5”
From Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity (2025) · cites this paper as [5]
Citations
Cites
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
Trends in diabetes treatment and control in U.S. adults, 1999-2018
Fang, M., Wang, D., Coresh, J., & Selvin, E. (2021) · New England Journal of Medicine · doi:10.1056/nejmsa2032271 · Cited by 690
Tonidandel, S., & LeBreton, J. M. (2010) · Organizational Research Methods · doi:10.1177/1094428109341993 · Cited by 150
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146
Shao, H., Laxy, M., Benoit, S. R., Cheng, Y. J., Gregg, E. W., & Zhang, P. (2021) · Diabetes Care · doi:10.2337/dc20-2871 · Cited by 15
Self-citation
Cited by
Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity
Li, P., Varghese, J. S., Shah, M. K., Galindo, R. J., Pasquel, F. J., Ali, M. K., & Shao, H. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.40890 · Cited by 43
Self-citationKhedagi, A. M., Hoke, C., Kelsey, M. D., Coviello, A. D., Jones, W. S., Jackson, L. R., Patel, M. R., McGarrah, R. W., Pagidipati, N. J., & Shah, N. P. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100477 · Cited by 29
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Li, C., Guo, S., Huo, J., Gao, Y., Yan, Y., & Zhao, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.987081 · Cited by 13
“Higher costs might be barriers to dispensing new classes of antidiabetics for vulnerable patients, which might further lead to medical inequality (35, 36).”
BackgroundJack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf301 · Cited by 9
Metadata
- Authors
- Shao, H., Li, P., Guo, J., Fonseca, V., Shi, L., & Zhang, P.
- Affiliations
- University of Florida (US)
- Tulane University (US)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Shao, Hui
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-01-17
- Volume
- 45
- Issue
- 2
- Pages
- e32-e33
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4206205642
- Cited by
- 13
- References
- 5
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 1
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- type 2 diabetes, SGLT2 inhibitors, GLP-1 receptor agonists, socioeconomic factors, medication use, clinical needs, health disparities
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Socioeconomic Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Socioeconomic factors play a more important role than clinical needs in the use of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes. https://app.cochat.ai/papers/10.2337/dc21-1800
- The paper
- Shao, H., Li, P., Guo, J., Fonseca, V., Shi, L., & Zhang, P. (2022). Socioeconomic factors play a more important role than clinical needs in the use of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes. Diabetes Care. https://doi.org/10.2337/dc21-1800
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.